Pricing and Reimbursement of Pharmaceuticals in the US: A data-driven analysis (2024)
Navigating the Complexities of US Drug Pricing & Reimbursement
Explore the intricacies of pharmaceutical pricing and reimbursement in the US with our latest report, Pricing and Reimbursement of Pharmaceuticals in the US: A Data-Driven Analysis (2024). This report delves into the top 57 drugs reimbursed through Medicare, providing detailed insights into expenditure, prescriptions, and claimant metrics. Understand the impact of the Inflation Reduction Act and gain strategic insights into the evolving landscape of Medicare Part D.
This comprehensive analysis offers valuable perspectives for pharmaceutical professionals, providing insights needed to navigate the complexities of US drug pricing and reimbursement.
Companies
AbbVie, Amgen, Novartis, Teva, Lilly, GSK, AstraZeneca, Sanofi, UCB, Pfizer, Merck Sharp & Dohme, Merck & Co., Bristol Myers Squibb, Biogen, Incyte, Gilead Sciences, Astellas, Sunovion, Novo Nordisk, Boehringer Ingelheim, Bausch Health, Exelixis, Neurocrine Biosciences, Amarin, Johnson & Johnson, Pharmacyclics, Salix Pharmaceuticals, Viiv Healthcare, Celgene, Viatris, Actelion, Sumitomo Pharma America
- Subject synopsis
- Research methodology and objectives
- Overview: Medicare and Medicaid
- Medicare Part D overview
- Manufacturers in 2022
- Top 10 branded drugs in 2022
- Top 10 non-branded drugs in 2022
- Medicare Drug Price Negotiation Program
- Medicare Part D top 57 summary
- Top 57 Medicare Part D expenditure
- Medicaid pharmaceutical expenditure overview
- Manufacturers in 2022
- Top 10 branded drugs in 2022
- Top 10 non-branded drugs in 2020
- Top 57 drugs Medicaid expenditure
- Top 57 drugs reimbursed by Medicare
- Advair Diskus
- Summary
- Advair Diskus: Medicare and Medicaid expenditure
- Anoro Ellipta
- Summary
- Anoro Ellipta: Medicare and Medicaid expenditure
- Aubagio
- Summary
- Aubagio: Medicare and Medicaid expenditure
- Austedo
- Summary
- Austedo: Medicare and Medicaid expenditure
- Biktarvy
- Summary
- Biktarvy: Medicare and Medicaid expenditure
- Breo Ellipta
- Summary
- Breo Ellipta: Medicare and Medicaid expenditure
- Cabometyx/Cometriq
- Summary
- Cabometyx/Cometriq: Medicare and Medicaid expenditure
- Calquence
- Summary
- Calquence: Medicare and Medicaid expenditure
- Copaxone
- Summary
- Copaxone: Medicare and Medicaid expenditure
- Eliquis
- Summary
- Eliquis: Medicare and Medicaid expenditure
- Enbrel
- Summary
- Enbrel: Medicare and Medicaid expenditure
- Entresto
- Summary
- Entresto: Medicare and Medicaid expenditure
- Epclusa
- Summary
- Epclusa: Medicare and Medicaid expenditure
- Erleada
- Summary
- Erleada: Medicare and Medicaid expenditure
- Farxiga
- Summary
- Farxiga: Medicare and Medicaid expenditure
- Genvoya
- Summary
- Genvoya: Medicare and Medicaid expenditure
- Harvoni
- Summary
- Harvoni: Medicare and Medicaid expenditure
- Humalog
- Summary
- Humalog: Medicare and Medicaid expenditure
- Humira
- Summary
- Humira: Medicare and Medicaid expenditure
- Ibrance
- Summary
- Ibrance: Medicare and Medicaid expenditure
- Imbruvica
- Summary
- Imbruvica: Medicare and Medicaid expenditure
- Ingrezza
- Summary
- Ingrezza: Medicare and Medicaid expenditure
- Invega
- Summary
- Invega: Medicare and Medicaid expenditure
- Jakafi
- Summary
- Jakafi: Medicare and Medicaid expenditure
- Janumet
- Summary
- Janumet: Medicare and Medicaid expenditure
- Januvia
- Summary
- Januvia: Medicare and Medicaid expenditure
- Jardiance
- Summary
- Jardiance: Medicare and Medicaid expenditure
- Lantus
- Summary
- Lantus: Medicare and Medicaid expenditure
- Latuda
- Summary
- Latuda: Medicare and Medicaid expenditure
- Levemir
- Summary
- Levemir: Medicare and Medicaid expenditure
- Linzess
- Summary
- Linzess: Medicare and Medicaid expenditure
- Lyrica
- Summary
- Lyrica: Medicare and Medicaid expenditure
- Novolog
- Summary
- Novolog: Medicare and Medicaid expenditure
- Ofev
- Summary
- Ofev: Medicare and Medicaid expenditure
- Opsumit
- Summary
- Opsumit: Medicare and Medicaid expenditure
- Ozempic
- Summary
- Ozempic: Medicare and Medicaid expenditure
- Pomalyst
- Summary
- Pomalyst: Medicare and Medicaid expenditure
- Restasis
- Summary
- Restasis: Medicare and Medicaid expenditure
- Revlimid
- Summary
- Revlimid: Medicare and Medicaid expenditure
- Spiriva
- Summary
- Spiriva: Medicare and Medicaid expenditure
- Stelara
- Summary
- Stelara: Medicare and Medicaid expenditure
- Symbicort
- Summary
- Symbicort: Medicare and Medicaid expenditure
- Tagrisso
- Summary
- Tagrisso: Medicare and Medicaid expenditure
- Tecfidera
- Summary
- Tecfidera: Medicare and Medicaid expenditure
- Tivicay
- Summary
- Tivicay: Medicare and Medicaid expenditure
- Tradjenta
- Summary
- Tradjenta: Medicare and Medicaid expenditure
- Trelegy Elipta
- Summary
- Trelegy Elipta: Medicare and Medicaid expenditure
- Tresiba
- Summary
- Tresiba: Medicare and Medicaid expenditure
- Triumeq
- Summary
- Triumeq: Medicare and Medicaid expenditure
- Trulicity
- Summary
- Trulicity: Medicare and Medicaid expenditure
- Vascepta
- Summary
- Vascepta: Medicare and Medicaid expenditure
- Vimpat
- Summary
- Vimpat: Medicare and Medicaid expenditure
- Vyndamax
- Summary
- Vyndamax: Medicare and Medicaid expenditure
- Xarelto
- Summary
- Xarelto: Medicare and Medicaid expenditure
- Xifaxan
- Summary
- Xifaxan: Medicare and Medicaid expenditure
- Xtandi
- Summary
- Xtandi: Medicare and Medicaid expenditure
- Zytiga
- Summary
- Zytiga: Medicare and Medicaid expenditure
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook